Cat. #154647
ZH3D7 somatic hybrid cell line panel
Cat. #: 154647
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Cancer Model
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Erasmus University Medical Center (Erasmus MC)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: ZH3D7 somatic hybrid cell line panel
- Cancer: Gynaecologic cancer
- Cancers detailed: Mammary ductal carcinoma
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: ZH3D7
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Cancer Model
- Conditional: No
- Description: Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied random insertional mutagenesis using defective retroviruses to identify the main genes conferring estrogen independence. Out of 15 candidate BCAR genes, several including BCAR1 and BCAR2 were shown to directly underlie estrogen independence. Somatic cell fusions were generated for these two genes in the hygromycin-B-resistant variant of ZR-75-1 breast cancer cells (ZH3D7) resulting in a panel of 3 cell lines (Cat No 154639-154641). These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression and therapy resistance.
- Production details: Hygromycin-B-resistant variants of ZR-75-1 cells, ZH3D7, were used as recipients in the somatic-cell-fusion experiments. Donor cells were two different anti-estrogen-resistant cell lines. Approximately 6 million donor cells, which were gamma-irradiated with approx 40 Gy and 3 million recipient cells were plated in 25cm flasks in RBCS medium with estradiol. After strong adherence to the flasks in 36 to 48 hr, cells were washed 3 times in RPMI-1640 without serum and incubated with 1 ml polyethy...
Target Details
- Target: BCAR1, BCAR2
Applications
- Application notes: These cell lines are resistant to hygromycin and Geneticin and are maintained in RBCS medium with estradiol and Geneticin. Since they carry a BCAR gene, that can also proliferate slowly in medium without estradiol and supplemented with anti-estrogen.
Handling
- Format: Frozen
- Growth medium: RBCS medium containing estradiol and Geneticin (G418)
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.
- Dorssers et al. 1997. Int J Cancer. 72(4):700-5. PMID: 9259413.
